A U.S. District Court judge’s recent decision to invalidate patents on two genes commonly tested to determine risk for breast and ovarian cancers is an important step toward removing legal hurdles that have slowed the development of new genetic testing technology, according to a team of Duke University researchers. [More]
The material in this press release comes from the originating research organization. Content may be edited for style and length. Want more? Sign up for our daily email.